|
| 迈威生物-U(688062)限售解禁 | | 解禁日期 | 本期流通股本
(万股) | 本期流通股本占
总股本比例(%) | 已流通股本
(万股) | 未流通股本
(万股) | 流通A股
(万股) | 流通A股占
总股本比例(%) | 限售股类型 | | 2025-07-18 | 16936.00 | 42.38% | 37353.00 | 2607.00 | 20417.00 | 51.09% | 追加承诺限售股份上市流通 | | 2024-01-18 | 287.36 | 0.72% | 20417.00 | 19543.00 | 20205.22 | 50.56% | 首发战略配售股份 | | 2023-01-18 | 10671.98 | 26.71% | 20129.64 | 19830.36 | 20129.64 | 50.37% | 首发原股东限售股份,首发战略配售股份 | | 2022-07-18 | 565.66 | 1.42% | 9457.66 | 30502.34 | 9457.66 | 23.67% | 首发机构配售股份 | | 2022-01-18 | 8892.00 | 22.25% | 8892.00 | 31068.00 | 8892.00 | 22.25% | 首发一般股份 |
|